Celeste Williams, MD
Cardiovascular Disease · Detroit, MINPI 1699843136
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Novartis at 41.2% of the total. Reporting peaked in 2019 at $30,744 and has fallen 58.9% since, to $12,634 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $666.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$29K
- Pfizer$25K
- Analog Devices Inc.$8K
- AstraZeneca$5K
- Abbott$3K
- Alnylam Pharmaceuticals Inc.$147
- plus $484 from 12 others
Across 15 payments — averaging $5378.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eidos Therapeutics, Inc.$28K
- Transmedics, Inc.$27K
- Amgen$23K
- Novartis$2K
What the payments were for
- Consulting fees$21,41331%
- Speaking & faculty fees$38,21755%
- Travel & lodging$7,06410%
- Food & beverage$3,2295%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $28,845 |
| Pfizer | 26 | $25,131 |
| Analog Devices Inc. | 1 | $7,500 |
| AstraZeneca | 11 | $5,333 |
| Abbott | 23 | $2,532 |
| Alnylam Pharmaceuticals Inc. | 1 | $147 |
| Novo Nordisk | 2 | $124 |
| Getinge USA Sales, LLC | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $38 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Procyrion, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Cordis US CORP. | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$28,466
- VYNDAQEL$7,858
- Sensinel CPM Wearable$7,500
- VYNDAMAX$6,476
- FARXIGA$1,477
- CardioMEMS HF System$1,245
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$421
- HeartMate 3 Left Ventricular Assist Device$179
- HeartMate 3 Left Ventricular Dev$158
- HeartMate$155
- ONPATTRO$147
- CARDIOHELP$100
How this compares
$69,972 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 79 | $1,869,744 |
| EntrestoSacubitril/Valsartan | 115 | $106,775 |
| EliquisApixaban | 73 | $73,813 |
| JardianceEmpagliflozin | 74 | $66,349 |
| FarxigaDapagliflozin Propanediol | 39 | $45,808 |
| Tacrolimus | 57 | $11,385 |
| Sirolimus | 19 | $6,704 |
| Bumetanide | 80 | $3,279 |
| Mycophenolate Mofetil | 28 | $1,482 |
| Amiodarone Hcl | 36 | $1,413 |
| Hydralazine Hcl | 55 | $1,408 |
| Carvedilol | 95 | $1,188 |
| Metoprolol Succinate | 45 | $1,086 |
| Potassium Chloride | 34 | $1,071 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $25,131 | $1,943,557152 claims |
| NovartisEntresto | $28,845 | $106,775115 claims |
| Boehringer IngelheimJardiance | $14 | $66,34974 claims |
| AstraZenecaFarxiga | $5,333 | $45,80839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Detroit
- Pedro Villablanca SpinettoDetroit$620K
- Wayne WeaverDetroit$340K
- Brian OneillDetroit$250K
- Karthikeyan AnanthasubramaniamDetroit$112K
- Gerald KoenigDetroit$96K
- David LanfearDetroit$82K
- Mahir ElderDetroit$68K
- Cori RussellDetroit$67K
- Pedro Engel GonzalezDetroit$66K
- James LeeDetroit$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.